

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 October 2022 (27.10.2022)



(10) International Publication Number
WO 2022/225941 A1

(51) International Patent Classification:

C07D 401/10 (2006.01) C07D 493/10 (2006.01)
C07D 401/14 (2006.01) A61K 31/4439 (2006.01)
C07D 405/14 (2006.01) A61K 31/444 (2006.01)
C07D 409/14 (2006.01) A61K 31/497 (2006.01)
C07D 413/14 (2006.01) A61K 31/4985 (2006.01)
C07D 471/04 (2006.01) A61K 31/506 (2006.01)
C07D 471/08 (2006.01) A61K 31/5377 (2006.01)
C07D 487/04 (2006.01) A61P 1/16 (2006.01)
C07D 491/048 (2006.01) A61P 3/04 (2006.01)
C07D 493/04 (2006.01) A61P 3/10 (2006.01)
C07D 493/08 (2006.01)

(21) International Application Number:

PCT/US2022/025364

(22) International Filing Date:

19 April 2022 (19.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/177,778 21 April 2021 (21.04.2021) US
63/286,475 06 December 2021 (06.12.2021) US

(71) Applicant: **GILEAD SCIENCES, INC.** [US/US]; 333
Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: **ARMSTRONG, Megan K.**; c/o Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California
94404 (US). **CASSIDY, James S.**; 750 Pine Street,
APT. 34, San Francisco, California 94108 (US). **CHIN, El-
bert**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster
City, California 94404 (US). **CHOU, Chienhung**; c/
o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City,
California 94404 (US). **COTTELL, Jeromy J.**; c/o Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California
94404 (US). **HUNG, Chao-I**; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US). **KO-
LAHDOUZAN, Kavoos**; 2001 McAllister Street, Apt. 211,
San Francisco, California 94118 (US). **LIN, David W.**; c/o
Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, Cal-
ifornia 94404 (US). **MITCHELL, Michael L.**; c/o Gilead


Sciences, Inc., 333 Lakeside Drive, Foster City, Califor-
nia 94404 (US). **ROBERTS, Ezra**; c/o Gilead Sciences,
Inc., 333 Lakeside Drive, Foster City, California 94404
(US). **SCHROEDER, Scott D.**; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).
SHAPIRO, Nathan D.; 2206 Coronet Boulevard, Belmont,
California 94002 (US). **TAYLOR, James G.**; c/o Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, Califor-
nia 94404 (US). **THOMAS-TRAN, Rhiannon**; c/o Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, Califor-
nia 94404 (US). **WRIGHT, Nathan E.**; 11520 Edgewood
Place, San Diego, California 92131 (US). **YANG, Zheng-
Yu**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster
City, California 94404 (US).

(74) Agent: **ROMEO, Russell J.** et al.; Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS



(57) Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

[Continued on next page]

WO 2022/225941 A1

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*